The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.

Gerlach, Daniel

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. [electronic resource] - Oncogene 05 2018 - 2687-2701 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1476-5594

10.1038/s41388-018-0150-2 doi


Animals
Antineoplastic Agents--administration & dosage
Cell Line, Tumor
Cell Survival--drug effects
Cyclin-Dependent Kinase 9--antagonists & inhibitors
Down-Regulation
Drug Synergism
Drug Therapy, Combination
Enhancer Elements, Genetic--drug effects
Flavonoids--administration & dosage
Gene Expression Profiling--methods
Gene Expression Regulation, Neoplastic--drug effects
HL-60 Cells
Humans
Leukemia, Myeloid, Acute--drug therapy
Mice
Piperidines--administration & dosage
Proteins--antagonists & inhibitors
Pyrazines--administration & dosage
RNA Polymerase II--metabolism
RNA-Binding Proteins--genetics
Transcription Factors
Triazoles--administration & dosage
Xenograft Model Antitumor Assays